Clinical Trials Logo

Clinical Trial Summary

The objective is to investigate the efficacy and safety of Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer.


Clinical Trial Description

Currently second-line treatment is the Anti-vascular combined chemotherapy, the third line standard is multi-target antivascular therapy, RIGONIVO research in three line treatment of good data, but failed to further validation in the real world, one of the reasons may be the third line therapy, patients physical score is relatively poor, immunotherapy to join may play a role,As we know, the PS score of all effective cases in the Rigonivo study was 0. Therefore, if the idea of antivascular combined immunotherapy is moved forward, it is possible to achieve better efficacy,Based on the above,The objective is to investigate the efficacy and safety of Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04929652
Study type Interventional
Source Jiangsu Cancer Institute & Hospital
Contact Liangjun Zhu
Phone +8613770575447
Email zhulj98@foxmail.com
Status Recruiting
Phase Phase 1/Phase 2
Start date June 1, 2021
Completion date June 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Recruiting NCT06200363 - A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer Phase 1
Not yet recruiting NCT02923622 - Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer N/A
Completed NCT01723969 - Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Active, not recruiting NCT00309179 - A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors Phase 2
Completed NCT03699111 - Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Not yet recruiting NCT02826837 - LEAC-102 for Advanced Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05077839 - Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC Phase 2
Recruiting NCT04324476 - A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer Phase 2
Not yet recruiting NCT06369259 - Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer Phase 2
Completed NCT00707889 - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer Phase 2
Terminated NCT01271166 - Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer Phase 1
Completed NCT00386828 - Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial Phase 2
Recruiting NCT04764006 - Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study Phase 2
Active, not recruiting NCT04835324 - Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Active, not recruiting NCT02619435 - Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer Phase 2
Completed NCT01822444 - ANGIOPREDICT. ICORG 12-16, V3
Completed NCT00498407 - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer Phase 2
Recruiting NCT05731336 - A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
Active, not recruiting NCT04744831 - Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer Phase 2